Full-Time

Global Sales Operations Analyst

Confirmed live in the last 24 hours

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Develops medical devices for vascular conditions

Biotechnology
Healthcare

Compensation Overview

$90k - $115kAnnually

+ Competitive Compensation Package + Equity Program

Mid

Company Historically Provides H1B Sponsorship

Alameda, CA, USA

Hybrid position; requires some in-office work.

Category
Customer Success Management
Sales & Account Management
Required Skills
Financial analysis
Tableau
Data Analysis
Excel/Numbers/Sheets

You match the following Penumbra Inc's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree in related field with 3+ years of finance, accounting, business planning or analytics experience or an equivalent combination of education and experience
  • Requires strong financial analysis skills and an ability to problem solve and make relevant recommendations
  • Proficiency with Tableau or similar data visualization tool highly desired
  • Strong oral, written and interpersonal communication skills
  • High degree of accuracy and attention to detail
  • Proficiency with Microsoft Office programs, with advanced modeling skills in Excel
  • Excellent organizational skills with ability to prioritize assignments while handling various projects simultaneously
Responsibilities
  • Contribute to developing and sharing sales analytics to accelerate revenue recognition in support of corporate goals
  • Ensure data accuracy in sales reporting system and act as a contact for sales dashboards
  • Assist with implementation of continuous system improvements through working with IT and sales management
  • Participate in delivering training to increase sales report adoption among field sales, sales managers, and senior executive team
  • Support the development of annual compensation, quota, and commissions plans
  • Analyze the effectiveness of various promotional activities and provide recommendations for improvement
  • Ensure sales territory alignments are accurately maintained, approved, and documented
  • Facilitate coordinating group efforts with Customer Service, Supply Chain, Legal, IT, and Contracts & Pricing to enable field sales team to minimize administrative efforts
  • Identify and implement opportunities for continued improvement of business processes and systems
  • Work with Sales Operations team members to improve global sales data reporting
  • Facilitate Sales Operations team project management
  • Adhere to the Company’s Quality Management System (QMS) as well as domestic and global quality system regulations, standards, and procedures
  • Understand relevant security, privacy and compliance principles and adhere to the regulations, standards, and procedures that are applicable to the Company
  • Ensure other members of the department follow the QMS, regulations, standards, and procedures
  • Perform other work-related duties as assigned
Desired Qualifications
  • Medical device, pharmaceutical, biotech, or other regulated industry experience desired

Penumbra Inc. specializes in creating medical devices aimed at treating neurovascular and peripheral vascular conditions. Their products include a variety of devices for neuro interventions, such as the Penumbra System and the Penumbra SMART COIL, which are used to address issues like stroke. For peripheral vascular diseases, they offer the Indigo System and related devices. These products are designed to assist healthcare professionals in hospitals and clinics, primarily in Europe and the Americas. Penumbra differentiates itself from competitors by focusing on specialized solutions for complex medical conditions and maintaining a strong commitment to research and development to enhance their offerings. The company's goal is to provide effective and high-quality medical devices that meet the needs of healthcare providers and improve patient outcomes.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$116.7K

Headquarters

Alameda, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Penumbra's revenue grew by 13.4% in 2024, indicating strong financial performance.
  • Expansion in Costa Rica will increase manufacturing capacity and meet growing demand.
  • The EMBOLIZE trial could lead to new treatment options and market opportunities.

What critics are saying

  • Layoffs in the Immersive Healthcare division suggest potential financial or strategic challenges.
  • Italian payback provision impacted financial results, posing challenges in the European market.
  • Operational challenges in Costa Rica expansion could affect production targets.

What makes Penumbra Inc unique

  • Penumbra offers a comprehensive range of neuro and peripheral vascular devices.
  • The company focuses on innovative solutions for stroke and neurovascular disease treatment.
  • Penumbra's global presence spans North and South America, Europe, Australia, and Asia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Investing.com
Feb 19th, 2025
UBS raises Penumbra stock price target to $320, keeps buy rating

Penumbra plans to expand its manufacturing capacity with a new facility in Costa Rica.

PR Newswire
Feb 18th, 2025
Penumbra, Inc. Reports Fourth Quarter And Full Year 2024 Financial Results

ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. Financial Highlights: Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023. Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to the full year 2023

PR Newswire
Jan 21st, 2025
Penumbra, Inc. Schedules Fourth Quarter And Full Year 2024 Earnings Release And Conference Call For February 18, 2025

ALAMEDA, Calif., Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. A press release with fourth quarter and full year 2024 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcast will be available on the company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity

Interventional News
Jan 10th, 2025
Interventional News' top 10 most popular stories of 2024

The Society of Interventional Radiology (SIR) Foundation, The VIVA Foundation and Penumbra, today announced the launch of the EMBOLIZE trial, a first-of-its-kind prospective, randomised controlled trial studying the effects of ovarian vein embolization (OVE) and pelvic vein embolization in reducing pain in women experiencing chronic pelvic pain due to pelvic venous disease (PeVD).

PR Newswire
Dec 30th, 2024
Penumbra, Inc. To Present At The 43Rd Annual J.P. Morgan Healthcare Conference

ALAMEDA, Calif., Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. Event:     43rd Annual J.P. Morgan Healthcare ConferenceDate:       Monday, January 13, 2025Time:      6:00pm ET/3:00pm PT